{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:26Z","timestamp":1791478046711,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Iron deficiency (ID) is common among patients with heart failure (HF), and it is associated with poor functional outcomes, increased hospitalizations, and higher mortality. This meta-analysis evaluates the efficacy of intravenous ferric carboxymaltose (FCM) in HF patients with ID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a literature search of major bibliographic databases up to 15 April 2025, to identify randomized controlled trials (RCTs) comparing FCM with placebo or standard care in HF patients with ID. The primary outcome was a composite of recurrent hospitalizations for heart failure (HHF) or cardiovascular (CV) death assessed at 1-year and complete follow-up. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were estimated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven RCTs enrolling 6493 patients (3329 FCM; 3164 control) were included. The mean age of patients was 66.7 \u00b1 10.6 years, 34.4% were women, mean left ventricular ejection fraction was 33.7 \u00b1 8.8%, mean haemoglobin was 12.4 \u00b1 1.8\u2005g\/dL, and mean transferrin saturation was 18.9 \u00b1 10.1%. FCM significantly reduced the composite of recurrent HHF or CV death at 1-year (RR 0.73, 95% CI 0.62\u20130.85) and over maximum follow-up (RR 0.80, 95% CI 0.68\u20130.94) compared to control. Recurrent HHF was significantly reduced with FCM administration (1-year RR 0.69, 95% CI 0.57\u20130.84; complete follow-up RR 0.75, 95% CI 0.60\u20130.94). FCM demonstrated a trend towards reduced all-cause (RR: 0.86, 95% CI: 0.74\u20131.00) and CV mortality at 1-year (RR: 0.86, 95% CI: 0.72\u20131.02), but this effect was attenuated over longer follow-up. FCM significantly improved 6-minute walk test performance (MD 29.19\u2005m, 95% CI 11.95\u201346.43). The trial sequential analysis confirmed robust evidence for the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intravenous FCM in HF patients is associated with reduced risk of adverse cardiovascular events and improved functional capacity. Further trials are needed to clarify its long-term survival impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvaf018","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:26:46Z","timestamp":1767702406000},"source":"Crossref","is-referenced-by-count":4,"title":["Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9872-8224","authenticated-orcid":false,"given":"Mushood","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rawalpindi Medical University , Rawalpindi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeshal","family":"Zulfiqar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tallal Mushtaq","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rawalpindi Medical University , Rawalpindi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohma","family":"Zia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rawalpindi Medical University , Rawalpindi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadiah","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rawalpindi Medical University , Rawalpindi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Naveed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-7314","authenticated-orcid":false,"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Brompton Hospital , London \u00a0","place":["UK"]},{"name":"National Heart and Lung Institute, Imperial College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal S","family":"Rana","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Kaiser Permanente Northern California , Oakland, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Greene","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute Division of Cardiology, , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute Division of Cardiology, , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Mentz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute Division of Cardiology, , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, University of California Los Angeles , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026021112474072200_xvaf018-B1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"2026021112474072200_xvaf018-B2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jamacardio.2016.1161","article-title":"Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure","volume":"1","author":"Cleland","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026021112474072200_xvaf018-B3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/jcm11010125","article-title":"Iron deficiency in heart failure: mechanisms and pathophysiology","volume":"11","author":"Alnuwaysir","year":"2021","journal-title":"J Clin Med"},{"key":"2026021112474072200_xvaf018-B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol"},{"key":"2026021112474072200_xvaf018-B6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"2026021112474072200_xvaf018-B7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026021112474072200_xvaf018-B8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","article-title":"Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure","volume":"35","author":"Jankowska","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B9","doi-asserted-by":"publisher","first-page":"e001153","DOI":"10.1136\/openhrt-2019-001153","article-title":"Iron deficiency in 78 805 people admitted with heart failure across England: a retrospective cohort study","volume":"7","author":"Beattie","year":"2020","journal-title":"Open Heart"},{"key":"2026021112474072200_xvaf018-B10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B11","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021112474072200_xvaf018-B12","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021112474072200_xvaf018-B13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ehf2.14905","article-title":"Intravenous iron therapy for heart failure and iron deficiency: an updated meta-analysis of randomized clinical trials","volume":"12","author":"Ahmed","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021112474072200_xvaf018-B15","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency","volume":"31","author":"Anker","year":"2025","journal-title":"Nat Med"},{"key":"2026021112474072200_xvaf018-B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026021112474072200_xvaf018-B17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026021112474072200_xvaf018-B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026021112474072200_xvaf018-B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026021112474072200_xvaf018-B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial sequential analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"2026021112474072200_xvaf018-B21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5603\/cj.97253","article-title":"Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction","volume":"31","author":"Drozd","year":"2024","journal-title":"Cardiol J"},{"key":"2026021112474072200_xvaf018-B22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021112474072200_xvaf018-B23","doi-asserted-by":"publisher","first-page":"FSO467","DOI":"10.2144\/fsoa-2019-0156","article-title":"Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency","volume":"6","author":"Dhoot","year":"2020","journal-title":"Future Sci OA"},{"key":"2026021112474072200_xvaf018-B24","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.3390\/nu14235057","article-title":"Effect of ferric carboxymaltose supplementation in patients with heart failure with preserved ejection fraction: role of attenuated oxidative stress and improved endothelial function","volume":"14","author":"Mollace","year":"2022","journal-title":"Nutrients"},{"key":"2026021112474072200_xvaf018-B25","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/eurheartj\/ehab411","article-title":"The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial","volume":"42","author":"Martens","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B26","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026021112474072200_xvaf018-B27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ehf2.12250","article-title":"Single-dose intravenous iron in Southeast Asian heart failure patients: a pilot randomized placebo-controlled study (PRACTICE-ASIA-HF)","volume":"5","author":"Yeo","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026021112474072200_xvaf018-B28","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"Van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2026021112474072200_xvaf018-B29","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2025.3833","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2 DZHK05 randomized clinical trial","volume":"333","author":"Anker","year":"2025","journal-title":"JAMA"},{"key":"2026021112474072200_xvaf018-B30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ejhf.2810","article-title":"Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis","volume":"25","author":"Graham","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021112474072200_xvaf018-B31","doi-asserted-by":"publisher","first-page":"2367956","DOI":"10.1080\/20565623.2024.2367956","article-title":"Ferric carboxymaltose for iron deficiency in patients with heart failure: a systematic review and meta-analysis","volume":"10","author":"Rangwala","year":"2024","journal-title":"Future Sci OA"},{"key":"2026021112474072200_xvaf018-B32","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3742","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): sex-specific outcomes","author":"Karakas","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021112474072200_xvaf018-B33","doi-asserted-by":"publisher","first-page":"ehae666.3278","DOI":"10.1093\/eurheartj\/ehae666.3278","article-title":"Efficacy and safety of intravenous iron therapy in heart failure patients with iron deficiency: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Abouzid","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021112474072200_xvaf018-B34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/diseases12120339","article-title":"The efficacy and safety of ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency: an updated systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Padda","year":"2024","journal-title":"Diseases"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvaf018\/66527103\/xvaf018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf018\/66527103\/xvaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvaf018\/66527103\/xvaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:47:49Z","timestamp":1770832069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvaf018\/8436247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvaf018","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,8]]},"article-number":"xvaf018"}}